Mitsubishi Tanabe Pharma America to Present Data on Investigational ND0612 at the 2024 Annual Meeting of the Parkinson Study Group [Yahoo! Finance]
MITSUBISHI CH GRP U/ADR (MTLHY)
NASDAQ:AMEX Investor Relations:
mitsubishichem-hd.co.jp/english/ir
Company Research
Source: Yahoo! Finance
the Parkinson Study Group, including data from the open-label, Phase 2b BeyoND study and a characterization of infusion site reactions (ISRs) reported from treatment with ND0612 in clinical studies. ND0612 is an investigational drug-device combination therapy, a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). The BeyoND study is an open-label, Phase 2b study that evaluated the safety and efficacy of investigational ND0612 over three years in people with PD experiencing motor fluctuations. The study's findings will be presented at the 2024 Annual Meeting of the Parkinson Study Group, but specific results are not mentioned in the article. Mitsubishi Tanabe Pharma America's goal is to support the Parkinson's disease com
Show less
Read more
Impact Snapshot
Event Time:
MTLHY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTLHY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTLHY alerts
High impacting MITSUBISHI CH GRP U/ADR news events
Weekly update
A roundup of the hottest topics
MTLHY
News
- Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items [Yahoo! Finance]Yahoo! Finance
- Mitsubishi Tanabe Pharma America Announces Research Collaboration Between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to Advance Small Molecule Condensate Modulator for ALS [Yahoo! Finance]Yahoo! Finance
- Classiq, Deloitte Tohmatsu, and Mitsubishi Chemical Compress Quantum Circuits by Up to 97% [Yahoo! Finance]Yahoo! Finance
- Government of Canada announces investment in Québec-based Aramis Biotechnologies [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS [Yahoo! Finance]Yahoo! Finance